European Archives - Page 30 of 1145 - European Medical Journal

Iron and Alcohol Interactions Drive Liver Disease Risk

A new retrospective study has proposed a predictive model for cirrhosis and hepatocellular carcinoma in individuals with haemochromatosis.

New investor network targets women’s health gap

WHAM’s Innovator’s Circle unites top funds to address the women’s health investment gap.

Oral Azithromycin Prescribing Practices for Community-Acquired Pneumonia

This study provides a timely examination of antibiotic prescribing practices in the emergency department, a critical frontline in the…

Survival Factors in Colorectal Cancer with Immune Checkpoint Inhibitors

A new study of 18,932 metastatic colorectal cancer patients reveals that microsatellite instability, albumin levels, and antibiotic use significantly impact survival rates when treated with immune checkpoint inhibitors, offering insights for personalised treatment.

Treatment Methods Compared for Overactive Bladder in MS

Findings suggest that both TPTNS and rTMS may have value in symptom management and quality-of-life improvement in MS patients with neurogenic OAB.

Anti-Inflammatory Therapy Reduces Vascular Risk in Rheumatoid Arthritis

Anti-inflammatory treatment in RA patients significantly reduced biomarkers like IL-8 and E-selectin, with PET/CT imaging confirming corresponding decreases in arterial inflammation.

Study Confirms Airborne Spread of H5N1 Influenza Virus

A recent study confirms that an H5N1 avian influenza virus isolated from a dairy farm worker can spread through the air between mammals.

Major Treatment Gap for Drug-Resistant Infections in Low/Middle-Income Countries

A major treatment gap for life-threatening carbapenem-resistant Gram-negative bacterial infections has been revealed across eight low- and middle-income countries.

Breakthrough in Human Antibodies for Snakebite Treatment

Each year, up to 138,000 people die and around 400,000 more are left permanently disabled from snakebites.

Trump’s drug pricing order hits pharma stocks

Trump’s “most-favoured nation” drug pricing plan shakes pharma markets, sparking losses for US and EU firms.